IMNM

Immunome Inc.

Nasdaq · Pharmaceutical Preparations · Inc. DE · CIK 0001472012

$18.38 +0.11% $2.1B

Insider Selling Cluster (4 insiders)High Impact Filing (7/10)14 New Institutional Positions8 Institutional Exits

Vol

Market Cap$2.1B

Cap SizeMid Cap

Analyst ConsensusStrong Buy (95%)

Inst. Holders50 funds

Inst. Value$1.3B

Inst. Activity14 buys / 8 sells

Insider Activity5B / 5S

Insider Net $-$2.2M

SEC Reports7

Exchange Nasdaq·Sector Pharmaceutical Preparations·Inc. DE·CIK 0001472012·Prev Close $18.36

Recent Activity

Jun 11, 2026 short_volume

Short Volume: IMNM — 76.4% short (0.5M / 0.7M)

Short: 507,775 | Exempt: 0 | TRF Vol: 664,385 | Short Ratio: 76.4% | Off-exchange volume (dark pool

Jun 10, 2026 Insider

SCHAFER CAROL was granted 9,897 shares

Director

Jun 10, 2026 Insider

Barchas Isaac was granted 9,897 shares

Director

Jun 10, 2026 Insider

Boylan James P was granted 9,897 shares

Director

May 28, 2026 SEC

Barclays initiates IMNM to Overweight — PT $36 (+66%)

ANALYST-UPGRADE — Impact 3/10

May 16, 2026 SEC

9 firms acted on IMNM: HC Wainwright & Co., Truist Securities, Goldman Sachs, Craig-Hallum, Evercore ISI Group, Lake Street, LifeSci Capital, Stephens & Co., Piper Sandler

ANALYST-UPGRADE — Impact 1/10

Apr 16, 2026 SEC

HC Wainwright initiated coverage on IMNM with a Buy rating and $40 price target, the highest among 13 analysts, implying

ANALYST-UPGRADE — Impact 7/10

Inst.

STATE STREET CORP — ADD

5,399,901 shares ($118.1M)

Price Targets

$35.77 +94.6% upside Strong Buy

Current $18.38 Low $30.00 Median $36.00 High $40.00 13 analysts

$30.00 $40.00

Analyst Ratings

Strong Buy95% buy · 21 analysts

6Strong Buy

14Buy

1Hold

0Sell

0Strong Sell

Recent Analyst Actions

Date	Firm	Action	Rating
Jun 12, 2026	Wedbush	REITERATE	Outperform → Outperform
May 28, 2026	Truist Securities	MAINTAIN	Buy → Buy
May 28, 2026	Barclays	INITIATE	Overweight
May 15, 2026	Leerink Partners	MAINTAIN	Outperform → Outperform
May 13, 2026	HC Wainwright & Co.	REITERATE	Buy → Buy

Earnings Estimates

Period	EPS Est.	Range	Growth	#
Current Q	$-0.50 ▼ -6.9%	$-0.64 — $-0.41	-1% YoY	12
Next Q	$-0.56 ▼ -4.8%	$-0.73 — $-0.48	14% YoY	12
Current FY	$-2.12 ▼ -0.8%	$-2.45 — $-1.84	13% YoY	12
Next FY	$-2.10 ▼ -2.1%	$-2.71 — $-1.71	1% YoY	11

Latest Reports

BULLISH ANALYST-UPGRADE 3/10

Barclays initiates IMNM to Overweight — PT $36 (+66%)

May 28, 2026

MIXED ANALYST-UPGRADE 7/10

HC Wainwright initiated coverage on IMNM with a Buy rating and $40 price target, the highest among 13 analysts, implying

Apr 16, 2026

Top Institutional Holders

Fund	Value	Move
FMR LLC	$371.1M	ADD
BlackRock, Inc.	$178.6M	ADD
STATE STREET CORP	$118.1M	ADD
WELLINGTON MANAGEMENT GROUP LLP	$103.5M	DOUBLED
VANGUARD CAPITAL MANAGEMENT LLC	$96.9M	—

Recent Insider Trades

Date	Insider	Type	Value
Jun 10, 2026	SCHAFER CAROL	A	$0.00
Jun 10, 2026	Barchas Isaac	A	$0.00
Jun 10, 2026	Boylan James	A	$0.00
Jun 10, 2026	BIENAIME JEAN	A	$0.00
Jun 10, 2026	SWAIN SANDRA	A	$0.00

50 institutional holders with $1.3B total value (61,119,934 shares) as of 2026-Q1. Top holders: FMR, BlackRock,, STATE. Net buying activity: 14 institutions added/increased vs 8 reduced.

Top Institutional Holders — 2026-Q1

#	Fund	Shares	Value	% of Tracked	Last Move
1	FMR LLC	16,969,954	$371.1M	27.8%	ADD +26.8%
2	BlackRock, Inc.	8,168,674	$178.6M	13.4%	ADD +30.4%
3	STATE STREET CORP	5,399,901	$118.1M	8.8%	ADD +39.6%
4	WELLINGTON MANAGEMENT GROUP LLP	4,731,977	$103.5M	7.7%	DOUBLED +406.4%
5	VANGUARD CAPITAL MANAGEMENT LLC	4,429,697	$96.9M	7.2%	—
6	DRIEHAUS CAPITAL MANAGEMENT LLC	4,099,901	$89.7M	6.7%	DOUBLED +432.0%
7	MORGAN STANLEY	2,841,589	$62.1M	4.6%	ADD +66.3%
8	Woodline Partners LP	1,575,398	$34.5M	2.6%	—
9	MARSHALL WACE, LLP	1,480,788	$32.4M	2.4%	DOUBLED +100.9%
10	GOLDMAN SACHS GROUP INC	1,101,476	$24.1M	1.8%	—
11	BNP Paribas Asset Management Holding S.A.	1,097,836	$24.0M	1.8%	DOUBLED +502.0%
12	VANGUARD PORTFOLIO MANAGEMENT LLC	1,006,975	$22.0M	1.6%	—
13	CHARLES SCHWAB INVESTMENT MANAGEMENT INC	851,789	$18.6M	1.4%	ADD +26.7%
14	Polar Capital Holdings Plc	849,479	$18.6M	1.4%	TRIM -25.1%
15	JANUS HENDERSON GROUP PLC	808,019	$17.7M	1.3%	—
16	BANK OF AMERICA CORP /DE/	781,607	$17.1M	1.3%	DOUBLED +285.6%
17	VANGUARD FIDUCIARY TRUST CO	716,395	$15.7M	1.2%	—
18	TD ASSET MANAGEMENT INC	694,934	$15.2M	1.1%	—
19	Nuveen, LLC	305,254	$6.7M	0.5%	ADD +80.3%
20	BALYASNY ASSET MANAGEMENT L.P.	251,396	$5.5M	0.4%	NEAR_EXIT -82.4%

Recent Position Changes

Fund	Action	Prev Shares	Curr Shares	Change %	Value	Quarter
STATE STREET CORP	ADD	3,868,000	5,399,901	+39.6%	$118.1M	2026-Q1
WELLINGTON MANAGEMENT GROUP LLP	DOUBLED	934,463	4,731,977	+406.4%	$103.5M	2026-Q1
MORGAN STANLEY	ADD	1,709,089	2,841,589	+66.3%	$62.1M	2026-Q1
MARSHALL WACE, LLP	DOUBLED	737,116	1,480,788	+100.9%	$32.4M	2026-Q1
BNP Paribas Asset Management Holding S.A.	DOUBLED	182,379	1,097,836	+502.0%	$24.0M	2026-Q1
BANK OF AMERICA CORP /DE/	DOUBLED	202,717	781,607	+285.6%	$17.1M	2026-Q1
Nuveen, LLC	ADD	169,346	305,254	+80.3%	$6.7M	2026-Q1
BALYASNY ASSET MANAGEMENT L.P.	NEAR_EXIT	1,429,680	251,396	-82.4%	$5.5M	2026-Q1
Universal- Beteiligungs- und Servicegesellschaft mbH	ADD	170,002	230,738	+35.7%	$5.0M	2026-Q1
Trexquant Investment LP	ADD	130,834	166,812	+27.5%	$3.6M	2026-Q1
Rafferty Asset Management, LLC	ADD	113,395	156,220	+37.8%	$3.4M	2026-Q1
AMERIPRISE FINANCIAL INC	TRIM	190,562	129,515	-32.0%	$2.8M	2026-Q1
ExodusPoint Capital Management, LP	NEAR_EXIT	779,578	115,370	-85.2%	$2.5M	2026-Q1
Cerity Partners LLC	ADD	42,792	83,581	+95.3%	$1.8M	2026-Q1
Invesco Ltd.	NEAR_EXIT	270,065	66,565	-75.4%	$1.5M	2026-Q1
SEI INVESTMENTS CO	ADD	27,719	52,770	+90.4%	$1.2M	2026-Q1
NISA INVESTMENT ADVISORS, LLC	TRIM	80,228	47,951	-40.2%	$1.0M	2026-Q1
VICTORY CAPITAL MANAGEMENT INC	DOUBLED	10,273	47,360	+361.0%	$1.0M	2026-Q1
DIMENSIONAL FUND ADVISORS LP	NEAR_EXIT	316,383	33,408	-89.4%	$730.6K	2026-Q1
LOS ANGELES CAPITAL MANAGEMENT LLC	NEAR_EXIT	59,417	8,281	-86.1%	$181.1K	2026-Q1
ASSETMARK, INC	ADD	3,093	4,535	+46.6%	$99.2K	2026-Q1
Point72 Asset Management, L.P.	EXIT	7,034,952	0	-100.0%	$0.00	2026-Q1
FMR LLC	ADD	13,056,709	16,549,716	+26.8%	$355.5M	2025-Q4
BlackRock, Inc.	ADD	5,822,736	7,594,996	+30.4%	$163.1M	2025-Q4
Point72 Asset Management, L.P.	ADD	4,824,504	7,034,952	+45.8%	$151.1M	2025-Q4

9 unique insiders with 18 transactions. Net insider value: -$2.2M ($764.7K bought, $2.9M sold).

Insider Transactions

Date	Insider	Title	Type	Shares	Price	Value
Jun 10, 2026	SCHAFER CAROL	Director	AWARD	9,897	—	—
Jun 10, 2026	Barchas Isaac	Director	AWARD	9,897	—	—
Jun 10, 2026	Boylan James P	Director	AWARD	9,897	—	—
Jun 10, 2026	BIENAIME JEAN JACQUES	Director	AWARD	9,897	—	—
Jun 10, 2026	SWAIN SANDRA M	Director	AWARD	9,897	—	—
Jun 10, 2026	WAGENHEIM PHILIP	Director	AWARD	9,897	—	—
Jun 5, 2026	BIENAIME JEAN JACQUES	Director	BUY	6,000	$19.48	$116.9K
Jun 5, 2026	BIENAIME JEAN JACQUES	Director	SELL	500	$19.44	$9.7K
May 15, 2026	BIENAIME JEAN JACQUES	Director	BUY	5,000	$20.70	$103.5K
Apr 2, 2026	Higgins Jack	Chief Scientific Officer	SELL	9,438	$21.64	$204.2K
Apr 2, 2026	Rosett Max	Chief Financial Officer	EXERCISE	31,848	$1.05	$33.4K
Apr 2, 2026	Rosett Max	Chief Financial Officer	SELL	63,656	$21.91	$1.4M
Mar 30, 2026	Higgins Jack	Chief Scientific Officer	GIFT	6,291	—	—
Mar 27, 2026	SIEGALL CLAY B	President and CEO	BUY	25,450	$19.67	$500.6K
Mar 23, 2026	WAGENHEIM PHILIP	Director	SELL	28,200	$20.65	$582.3K
Mar 20, 2026	WAGENHEIM PHILIP	Director	SELL	36,800	$20.47	$753.3K
Mar 11, 2026	BIENAIME JEAN JACQUES	Director	BUY	1,000	$21.55	$21.6K
Mar 10, 2026	BIENAIME JEAN JACQUES	Director	BUY	1,000	$22.12	$22.1K

7 SEC filing reports analyzed. Sentiment: 3 bullish, 0 bearish, 3 mixed, 1 neutral. Avg impact: 4.3/10.

BULLISH ANALYST-UPGRADE 3/10

Barclays initiates IMNM to Overweight — PT $36 (+66%)

May 28, 2026

MIXED ANALYST-UPGRADE 7/10

HC Wainwright initiated coverage on IMNM with a Buy rating and $40 price target, the highest among 1

Apr 16, 2026

BULLISH ANALYST-UPGRADE 1/10

9 firms acted on IMNM: HC Wainwright & Co., Truist Securities, Goldman Sachs, Craig-Hallum, Evercore ISI Group, Lake Street, LifeSci Capital, Stephens & Co., Piper Sandler

May 16, 2026

BULLISH 8-K 7/10

Immunome reported Q1 2026 results: net loss of $53.8M ($-0.48/share) vs consensus $-0.60, a beat of

May 12, 2026

NEUTRAL DEFA14A 2/10

Immunome Inc. filed a definitive proxy statement (DEFA14A) for an upcoming shareholder meeting, whic

Apr 24, 2026

MIXED CLUSTER 5/10

Immunome Inc. saw mixed insider activity with CEO Clay Siegall purchasing $501K of stock while Direc

Apr 1, 2026

MIXED CLUSTER 5/10

Analysis based on filing metadata only — document content was unavailable. Recent insider activity s

Mar 31, 2026

∅

No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.

Current analyst consensus: Strong Buy (95% buy). Based on 21 analysts: 6 strong buy, 14 buy, 1 hold, 0 sell, 0 strong sell.

Analyst Price Targets

$35.77 mean target +94.6% upside Strong Buy (1.23)

$30.00 Low $40.00 High

Metric	Value
Current Price	$18.38
Target Low	$30.00
Target Mean	$35.77
Target Median	$36.00
Target High	$40.00
# Analysts	13
Recommendation	Strong Buy (1.23)

Earnings Estimates & Revisions

Period	EPS Avg	EPS Low	EPS High	EPS Growth	30d Rev.	Up/Down	Rev. Avg	Rev. Growth	Analysts
Current Q 2026-06-30	$-0.50	$-0.64	$-0.41	-0.9%	-6.9%	9↑ 0↓	$0.0B	-95.8%	12
Next Q 2026-09-30	$-0.56	$-0.73	$-0.48	14.2%	-4.8%	9↑ 1↓	$0.0B	0.0%	12
Current FY 2026-12-31	$-2.12	$-2.45	$-1.84	12.6%	-0.8%	11↑ 1↓	$0.0B	-60.9%	12
Next FY 2027-12-31	$-2.10	$-2.71	$-1.71	1.3%	-2.1%	7↑ 2↓	$0.1B	2379.2%	11

Current Quarter EPS Revision History

Timepoint	EPS Estimate	Change
Current	$-0.505
7d ago	$-0.507	+0.002
30d ago	$-0.472	-0.033
60d ago	$-0.582	+0.077
90d ago	$-0.582	+0.077

7 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 2 initiations.

Individual Analyst Actions

Date	Analyst Firm	Action	Previous Rating	New Rating
Jun 12, 2026	Wedbush	REITERATE	Outperform	Outperform
May 28, 2026	Truist Securities	MAINTAIN	Buy	Buy
May 28, 2026	Barclays	INITIATE	—	Overweight
May 15, 2026	Leerink Partners	MAINTAIN	Outperform	Outperform
May 13, 2026	HC Wainwright & Co.	REITERATE	Buy	Buy
Mar 4, 2026	Craig-Hallum	MAINTAIN	Buy	Buy
Mar 4, 2026	Stephens & Co.	MAINTAIN	Overweight	Overweight
Feb 12, 2026	HC Wainwright & Co.	INITIATE	—	Buy
Jan 15, 2026	Wedbush	REITERATE	Outperform	Outperform

Monthly Consensus History

Period	Strong Buy	Buy	Hold	Buy %
Jun 1, 2026	6	14	1	95%
May 1, 2026	6	13	1	95%
Apr 1, 2026	6	13	1	95%
Mar 1, 2026	6	13	1	95%
Feb 1, 2026	6	12	1	95%
Jan 1, 2026	6	12	1	95%

Strong BuyBuyHoldSellStrong Sell

∅

No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.

∅

No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.

Jun 11, 2026

short_volume

Short Volume: IMNM — 76.4% short (0.5M / 0.7M)

Short: 507,775 | Exempt: 0 | TRF Vol: 664,385 | Short Ratio: 76.4% | Off-exchange volume (dark pool + OTC)

Jun 1, 2026

short_volume

Short Volume: IMNM — 73.4% short (0.6M / 0.8M)

Short: 577,607 | Exempt: 456 | TRF Vol: 786,680 | Short Ratio: 73.4% | Off-exchange volume (dark pool + OTC)

May 18, 2026

short_volume

Short Volume: IMNM — 72.4% short (0.4M / 0.6M)

Short: 426,157 | Exempt: 30 | TRF Vol: 588,868 | Short Ratio: 72.4% | Off-exchange volume (dark pool + OTC)

May 11, 2026

earnings_calendar

IMNM Q1 2026 Earnings Scheduled — 2026-05-11

May 7, 2026

earnings_calendar

IMNM Q1 2026 Earnings Scheduled — 2026-05-07

May 5, 2026

short_interest

FTD: IMNM — 26,679 shares ($0.6M) failed to deliver

Settlement: 20260505, Price: $23.33, FTD Value: $622,421.07, IMMUNOME INC

May 4, 2026

short_interest

FTD: IMNM — 24,998 shares ($0.6M) failed to deliver

Settlement: 20260504, Price: $22.73, FTD Value: $568,204.54, IMMUNOME INC

Apr 30, 2026

short_volume

Short Volume: IMNM — 67.9% short (0.4M / 0.6M)

Short: 408,659 | Exempt: 0 | TRF Vol: 602,179 | Short Ratio: 67.9% | Off-exchange volume (dark pool + OTC)

Mar 27, 2026

short_interest

FTD: IMNM — 38,935 shares ($0.8M) failed to deliver

Settlement: 20260327, Price: $20.41, FTD Value: $794,663.35, IMMUNOME INC

Mar 26, 2026

short_interest

FTD: IMNM — 41,555 shares ($0.8M) failed to deliver

Settlement: 20260326, Price: $20.30, FTD Value: $843,566.5, IMMUNOME INC

Mar 25, 2026

short_interest

FTD: IMNM — 45,225 shares ($0.9M) failed to deliver

Settlement: 20260325, Price: $20.21, FTD Value: $913,997.25, IMMUNOME INC

Mar 24, 2026

short_interest

FTD: IMNM — 45,362 shares ($0.9M) failed to deliver

Settlement: 20260324, Price: $20.75, FTD Value: $941,261.5, IMMUNOME INC

Feb 19, 2026

short_interest

FTD: IMNM — 50,283 shares ($1.1M) failed to deliver

Settlement: 20260219, Price: $21.99, FTD Value: $1,105,723.17, IMMUNOME INC

Feb 12, 2026

short_interest

FTD: IMNM — 28,622 shares ($0.7M) failed to deliver

Settlement: 20260212, Price: $23.41, FTD Value: $670,041.02, IMMUNOME INC